Clinical Trials Browser

Phase 3 × camrelizumab × 30 days × Clear all

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT07432087 2026-02-25

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck